iShares Nasdaq Biotechnology (IBB)

Add to Watchlists
Create an Alert
296.62 -0.08  -0.03% NASDAQ Oct 31, 8:00PM BATS Real time Currency in USD
View Full Chart
IBB Price Chart

IBB Description

iShares Nasdaq Biotechnology is a long only equity fund managed by iShares that tracks the NASDAQ Biotechnology TR USD index and has 6.198B USD assets under management. It has an expected distribution yield of 0.15%, a Forecasted PE Ratio of 29.57, and a Forecasted Price to Book Value of 6.620. The fund has a net expense ratio of 0.48%, turns over its positions 39.00% per year, and is traded on the NASDAQ.

IBB Key Info

Expense Ratio (7-31-14) 0.48%
Assets Under Management (10-31-14) 6.198B
30-Day Average Volume (10-30-14) 1.490M
Net Asset Value (10-31-14) 296.53
Discount or Premium to NAV (10-31-14) 0.03%
Turnover Ratio (3-31-14) 39.00%

IBB Asset Allocation

Type % Net % Long % Short
Cash 0.00% 0.00% 0.00%
Stock 99.98% 99.98% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.02% 0.02% 0.00%
As of Oct. 30, 2014

IBB Region Exposure

Americas 95.11%
North America 95.11%
Latin America 0.00%
Greater Europe 4.83%
United Kingdom 1.34%
Europe Developed 3.49%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.06%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.06%
Market Classification
% Developed Markets 99.94%
% Emerging Markets 0.06%
As of Oct. 17, 2014
Region breakdown data is calculated by using the long position holdings of the portfolio.

IBB Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Oct. 30, 2014

IBB Stock Market Capitalization

Giant 33.68%
Large 24.96%
Medium 22.05%
Small 10.28%
Micro 9.01%
As of Oct. 30, 2014
View More Holdings

IBB Top 10 Holdings

Name % Weight Price Chg %
Amgen Inc 8.77% 162.18 +0.37%
Celgene Corp 8.51% 107.09 +0.14%
Gilead Sciences Inc 8.03% 112.00 -1.94%
Regeneron Pharmaceuticals Inc 7.37% 393.72 +0.23%
Biogen Idec Inc 7.08% 321.08 +0.02%
Vertex Pharmaceuticals Inc 4.48% 112.64 +1.61%
Alexion Pharmaceuticals Inc 4.31% 191.36 -0.81%
Illumina Inc 4.08% 192.58 -0.43%
Mylan Inc 4.05% 53.55 +2.25%
Biomarin Pharmaceutical Inc 2.51% 82.50 +0.17%
As of Oct. 30, 2014
Get Quote for
Advertisement

IBB Basic Info

Style
Asset Class Sector Equity
Prospectus Objective Specialty - Health
Fund Owner Firm Name iShares
Benchmark Index
NASDAQ Biotechnology TR USD 100.0%
Key Dates
Inception Date 2/5/2001
Last Annual Report Date 3/31/2014
Last Prospectus Date 7/31/2014
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available RRSP No

IBB Manager Info

Name Tenure
Diane Hsiung 6.75 yrs
Greg Savage 6.75 yrs
Jennifer Hsui 2.17 yrs
Matthew Goff 1.01 yrs

IBB Risk Info

Beta 0.9621
30 Day Average Volatility 27.36%

IBB Fundamentals

Dividend Yield TTM (10-31-14) 0.15%
Weighted Average PE Ratio 35.29
Weighted Average Price to Sales Ratio 8.488
Weighted Average Price to Book Ratio 7.181
Weighted Median ROE 10.08%
Weighted Median ROA 1.51%
Forecasted Dividend Yield 0.23%
Forecasted PE Ratio 29.57
Forecasted Price to Sales Ratio 7.299
Forecasted Price to Book Ratio 6.620
Number of Holdings 118.00
As of Oct. 30, 2014

IBB Growth Estimates

Forecasted 5 Yr Earnings Growth 15.37%
Forecasted Book Value Growth 10.37%
Forecasted Cash Flow Growth 10.96%
Forecasted Earnings Growth 30.67%
Forecasted Revenue Growth 11.96%
As of Oct. 30, 2014

IBB Performance

  Returns Total Returns
1M 8.36% 8.36%
3M 15.26% 15.28%
6M 28.77% 29.00%
1Y 43.06% 43.31%
3Y 195.8% 197.9%
5Y 304.1% 309.4%
As of Oct. 31, 2014

IBB Flows

1M -48.29M
3M -140.28M
6M -186.88M
YTD 178.42M
1Y 241.02M
3Y 1.218B
5Y 685.01M
As of Sept. 30, 2014
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts Professional.
Start your Free 14-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 14 Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.